EDAP VS NVO Stock Comparison
Performance
EDAP10/100
10/100
EDAP returned -58.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
NVO100/100
100/100
NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
EDAP75/100
75/100
2 analysts offer 12-month price targets for EDAP. Together, they have an average target of 0, the most optimistic target put EDAP at 0 within 12-months and the most pessimistic has EDAP at 0.
NVO50/100
50/100
1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.
Sentiment
EDAP70/100
70/100
EDAP had a bullish sentiment score of 69.60% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 2.46 comments, and 1.77 likes per day.
NVO
"Sentiment" not found for NVO
Technicals
EDAP14/100
14/100
EDAP receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
NVO50/100
50/100
NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
EDAP10/100
10/100
EDAP has missed earnings 9 times in the last 20 quarters.
NVO46/100
46/100
NVO has missed earnings 3 times in the last 20 quarters.
Profit
EDAP42/100
42/100
Out of the last 20 quarters, EDAP has had 11 profitable quarters and has increased their profits year over year on 4 of them.
NVO90/100
90/100
Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.
Volatility
EDAP53/100
53/100
EDAP has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
NVO53/100
53/100
NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
All score calculations are broken down here to help you make more informed investing decisions
EDAP TMS SA Summary
Nasdaq / EDAP
Healthcare
Medical - Devices
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Novo-Nordisk A/S Summary
New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare EDAP to other companies in the same or a similar industry.